Akineton (Biperiden Hydrochloride) - Summary

AKINETON SUMMARY

AKINETON® Tablets
(biperiden hydrochloride)

Each AKINETON tablet for oral administration contains 2 mg biperiden hydrochloride. Other ingredients may include corn syrup, lactose, magnesium stearate, potato starch and talc. AKINETON is an anticholinergic agent. Biperiden is α-5-Norbornen-2-yl-α-phenyl-1-piperidinepropanol. It is a white, crystalline, odorless powder, slightly soluble in water and alcohol. It is stable in air at normal temperatures.

AKINETON (biperiden) is indicated for the following:

• As an adjunct in the therapy of all forms of parkinsonism (idiopathic, postencephalitic, arteriosclerotic)
• Control of extrapyramidal disorders secondary to neuroleptic drug therapy (e.g., phenothiazines)

NEWS HIGHLIGHTS

Published Studies Related to Akineton (Biperiden)

Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects. [2005.09]
RATIONALE: The central cholinergic system is implicated in cognitive functioning. The dysfunction of this system is expressed in many diseases like Alzheimer's disease, dementia of Lewy body, Parkinson's disease and vascular dementia. In recent animal studies, it was found that selective cholinergic modulation affects visuospatial processes even more than memory function. OBJECTIVE: In the current study, we tried to replicate those findings. In order to investigate the acute effects of cholinergic drugs on memory and visuospatial functions, a selective anticholinergic drug, biperiden, was compared to a selective acetylcholinesterase-inhibiting drug, rivastigmine, in healthy elderly subjects... CONCLUSIONS: These results implicate acetylcholine as a modulator not only of memory but also of visuospatial abilities.

Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions. [2008.12.03]
The effects of biperiden (0, 100, and 320 microg/kg), a selective muscarinic M(1)/M(4) receptor cholinergic antagonist, were studied alone and in combination with those of L-DOPA methyl ester (16.7 mg/kg), a selective dopamine D(1) receptor agonist SKF-82958 (74.8 microg/kg), or a selective D(2)/D(3) receptor agonist rotigotine (32 microg/kg) on circling behavior in MPTP induced hemiparkinsonian monkeys...

The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo-controlled study. [2007.06]
Neuroleptic-induced acute akathisia (NIA) is a distressing condition and an important clinical problem because it is associated with treatment noncompliance and suicidal or impulsive behavior. Anticholinergics are among the treatment options; however, a review of the literature fails to identify a double-blind, randomized, placebo-controlled study of these medications in NIA...

Biperiden-induced delirium model in rats: a behavioral and electroencephalographic study. [2006.10.18]
Aims and methods: In order to elucidate the neural mechanisms of delirium, we administered the anticholinergic drug, biperiden (40 mg/kg i.p.), to 10 adult male Wistar rats and examined the resulting polygraphic recordings, including electroencephalography (EEG), electrooculography (EOG), and electromyography (EMG), for 60 min following injection...

Administration of haloperidol with biperiden reduces mRNAs related to the ubiquitin-proteasome system in mice. [2005.06.15]
In order to find molecules affected by administration of an antipsychotic drug with an antimuscarinic drug, which is a common prescription used to prevent extrapyramidal adverse effects caused by the antipsychotic drugs, gene expression profiling in the frontal cortex was studied in mice...

more studies >>

Clinical Trials Related to Akineton (Biperiden)

Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence [Recruiting]
The aim of this study is to assess the efficacy of caffeine compared to placebo as a maintenance treatment for cocaine dependence. Caffeine potentiation with biperiden will be also studied.

Ninety patients with snorted/sniffed cocaine dependence will be randomized to receive

caffeine (300 - 1200 mg t. i.d.) plus biperidene (8 mg b. i.d.) caffeine (300 - 1200 mg

t. i.d.) with placebo or placebo during 10 days in an in-hospital setting.

Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients [Recruiting]
The aim of this study is to assess the efficacy of caffeine compared to placebo in detoxifying cocaine dependent patients. Caffeine potentiation with biperiden will be also studied.

108 with cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t. i.d.)

plus biperidene (8 mg b. i.d.) or caffeine (300 - 1200 mg t. i.d.) with placebo or placebo

during 6 months.

Primary efficacy outcomes will be 1) patient comfort assessed with abstinence symptomatology, craving for cocaine and mental status during detoxifying period, 2) study retention and 3) cocaine use.

Brain dopamine system will be assessed thru IBZM-SPECT and the apomorphine test.

Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD) [Not yet recruiting]
This study was designed to evaluate the pharmacokinetic profile, safety and efficacy in Parkinson's Disease patients.

more trials >>